CIK 0001812364 · Large accelerated filer
Relay Therapeutics, Inc.
Sign in to watch- Ticker
- RLAY
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-370-8837
- Business address
- 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $120,165,474
- in 11 filings, $3.7M under 10b5-1 plans
Net −$120,165,474. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 98 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-29 | Bergstrom Donald A President, R&D | Sale | −2,698 | $8.85 | $24K | 524,081 |
| 2024-07-29 | Adams Brian Chief Legal Officer | Sale | −1,638 | $8.85 | $14K | 323,834 |
| 2024-07-26 | Patel Sanjiv President and CEO | Option exercise 10b5-1 | +36,706 | $5.04 | $185K | 802,836 |
| 2024-07-26 | Patel Sanjiv President and CEO | Sale 10b5-1 | −36,706 | $9.07 | $333K | 766,130 |
| 2024-07-26 | Patel Sanjiv President and CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −36,706 | 482,073 | ||
| 2024-07-25 | Patel Sanjiv President and CEO | Option exercise 10b5-1 | +50,000 | $5.04 | $252K | 816,130 |
| 2024-07-25 | Patel Sanjiv President and CEO | Sale 10b5-1 | −50,000 | $9.16 | $458K | 766,130 |
| 2024-07-25 | Patel Sanjiv President and CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,000 | 518,779 | ||
| 2024-06-30 | Patel Sanjiv President and CEO | Grant or award | +2,108 | $5.54 | $12K | 766,130 |
| 2024-06-30 | Rahmer Peter See remarks | Grant or award | +2,108 | $5.54 | $12K | 434,288 |
| 2024-06-27 | Bergstrom Donald A President, R&D | Sale | −648 | $6.26 | $4K | 526,779 |
| 2024-06-27 | Rahmer Peter See remarks | Sale | −245 | $6.26 | $2K | 432,180 |
| 2024-06-27 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −295 | $6.26 | $2K | 339,508 |
| 2024-06-27 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −9,078 | $6.24 | $57K | 330,430 |
| 2024-06-27 | Adams Brian Chief Legal Officer | Sale | −295 | $6.26 | $2K | 325,472 |
| 2024-06-10 | Rubin Jami Director | Option exercise | +42,242 | $5.04 | $213K | 67,242 |
| 2024-06-10 | Rubin Jami Director | Option exercise · Stock Option (Right to Buy) | −42,242 | 0 | ||
| 2024-06-05 | Rahmer Peter See remarks | Sale 10b5-1 | −20,450 | $7.06 | $144K | 432,425 |
| 2024-06-04 | Rahmer Peter See remarks | Sale 10b5-1 | −40,595 | $6.64 | $270K | 452,875 |
| 2024-06-03 | Murcko Mark Director | Grant or award · Stock Option (Right to Buy) | +102,225 | 102,225 |
Page 9 of 17 · 329 trades